NICE Recommends Lynparza Tablets for Relapsed, BRCA-mutated Advanced Ovarian Cancers

NICE Recommends Lynparza Tablets for Relapsed, BRCA-mutated Advanced Ovarian Cancers
After an initial rejection due to cost-effectiveness concerns, the U.K.’s National Institute of Health and Care Excellence (NICE) has reversed its decision and is expanding the use of Lynparza (olaparib) tablets to include maintenance therapy for relapsed ovarian cancer patients who responded to platinum-based chemotherapy. The recommendation is for adults within the National Health System (NHS) of England and Wales, with epithelial ovarian, fallopian tube, or peritoneal cancer, who carry a BRCA mutation. Lynparza tablets will be made available via routine commissioning for patients who received three or more courses of platinum-based chemotherapy, or via the Cancer Drugs Fund — NHS's reserve to fund cancer therapies — to patients in England if they have had two courses of platinum-based chemotherapy. The treatment had been approved as a first-line maintenance therapy, and is now the first PARP inhi
Subscribe or to access all post and page content.